Results 211 to 220 of about 189,515 (386)
Economic Impact of Allergic Diseases and Asthma—The HEAD Pan‐European Registry
This registry‐based study demonstrates the substantial economic burden of allergic diseases across Europe with a high degree of heterogeneity between countries. Treatments and specialist visits are the primary drivers of healthcare costs. Asthma poses the highest disease burden.
Ioana Agache+66 more
wiley +1 more source
Osteitis Deformans (Paget's Bone Disease) with Chronic Eczema
Fabian Weber
openalex +1 more source
GWAS Identifies CACNA2D3 Associated With Asthma and Atopic Dermatitis Multimorbidity in Children
Allergy, EarlyView.
Dong Yun Kim+11 more
wiley +1 more source
Extremely asymmetric ectasia: Tomographically unilateral keratoconus
Abstract Purpose To investigate the characteristics of apparently stable forms of tomographically unilateral keratoconus (KC). Methods In this retrospective case–control study, strict unilaterality criteria were applied to select tomographically unilateral cases with ≥3 years of follow‐up.
Hasan Shabani+6 more
wiley +1 more source
The paste Treatment of Inflammatory Skin Diseases, especially of Eczema [PDF]
NULL AUTHOR_ID
openalex +1 more source
Godfrey Bingley was a British industrialist who took up geology, photography and travel in the 1880s. His photographs are housed at the University of Leeds, where he worked with its Chair of Geology. This article analyses the archive's projection of the imperial geological imaginary that emanated from Britain and extended to the Americas.
Rebecca Jarman
wiley +1 more source
INVASION OF THE BODY BY COCCI FROM THE SKIN IN ECZEMA [PDF]
NULL AUTHOR_ID
openalex +1 more source
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara+15 more
wiley +1 more source